XML 45 R32.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Segment Reporting Significant segment expenses, as provided to the CODM, are presented as the following:

 

 

 

Year Ended
December 31,

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

Tegoprubart - kidney transplantation programs

 

$

27,452

 

 

$

11,940

 

Tegoprubart - other development programs

 

 

306

 

 

 

3,186

 

Manufacturing

 

 

12,448

 

 

 

8,048

 

Personnel-related

 

 

10,706

 

 

 

8,351

 

Stock-based compensation

 

 

13,122

 

 

 

6,545

 

General and administrative expense

 

 

6,543

 

 

 

4,930

 

Total operating expenses

 

 

70,577

 

 

 

43,000

 

Loss from operations

 

 

(70,577

)

 

 

(43,000

)

Other income, net

 

 

3,924

 

 

 

2,674

 

Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds

 

 

30,900

 

 

 

(76,211

)

Provision for income taxes

 

 

(431

)

 

 

 

Segment and net loss

 

$

(36,184

)

 

$

(116,537

)